The combination therapy group included the full spectrum of cancers treated with PD-1/PD-L1 agents, in addition to malignancies such as pleural mesothelioma, acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), Hodgkin lymphoma, papillary thyroid carcinoma, and cutaneous squamous cell carcinoma (cSCC) (Table 3). The gene discussed is PDCD1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.